These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 27613250)

  • 1. Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies.
    Borte M; Kriván G; Derfalvi B; Maródi L; Harrer T; Jolles S; Bourgeois C; Engl W; Leibl H; McCoy B; Gelmont D; Yel L
    Clin Exp Immunol; 2017 Jan; 187(1):146-159. PubMed ID: 27613250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America.
    Suez D; Stein M; Gupta S; Hussain I; Melamed I; Paris K; Darter A; Bourgeois C; Fritsch S; Leibl H; McCoy B; Gelmont D; Yel L
    J Clin Immunol; 2016 Oct; 36(7):700-12. PubMed ID: 27582171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune globulin subcutaneous, human - klhw 20% for primary humoral immunodeficiency: an open-label, Phase III study.
    Sleasman JW; Lumry WR; Hussain I; Wedner HJ; Harris JB; Courtney KL; Mondou E; Lin J; Stein MR
    Immunotherapy; 2019 Nov; 11(16):1371-1386. PubMed ID: 31621458
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency.
    Wasserman RL; Melamed I; Stein MR; Engl W; Sharkhawy M; Leibl H; Puck J; Rubinstein A; Kobrynski L; Gupta S; Grant AJ; Ratnayake A; Richmond WG; Church J; Yel L; Gelmont D
    J Clin Immunol; 2016 Aug; 36(6):571-82. PubMed ID: 27220317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Multi‑Center, Open‑Label, Single‑Arm Trial to Evaluate the Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency.
    Santamaria M; Neth O; Douglass JA; Krivan G; Kobbe R; Bernatowska E; Grigoriadou S; Bethune C; Chandra A; Horneff G; Borte M; Sonnenschein A; Kralickova P; Ramón SS; Langguth D; Gonzalez-Granado LI; Alsina L; Querolt M; Griffin R; Hames C; Mondou E; Price J; Sanz A; Lin J
    J Clin Immunol; 2022 Apr; 42(3):500-511. PubMed ID: 34973143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.
    Kobayashi RH; Gupta S; Melamed I; Mandujano JF; Kobayashi AL; Ritchie B; Geng B; Atkinson TP; Rehman S; Turpel-Kantor E; Litzman J
    Front Immunol; 2019; 10():40. PubMed ID: 30778345
    [No Abstract]   [Full Text] [Related]  

  • 7. Immune globulin (human) 10 % liquid: a review of its use in primary immunodeficiency disorders.
    McCormack PL
    BioDrugs; 2013 Aug; 27(4):393-400. PubMed ID: 23703447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency.
    Wasserman RL; Melamed I; Stein MR; Gupta S; Puck J; Engl W; Leibl H; McCoy B; Empson VG; Gelmont D; Schiff RI;
    J Allergy Clin Immunol; 2012 Oct; 130(4):951-7.e11. PubMed ID: 22846381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate/chromatography purified in patients with primary immunodeficiency disease.
    Wasserman RL; Irani AM; Tracy J; Tsoukas C; Stark D; Levy R; Chen J; Sorrells S; Roberts R; Gupta S
    Clin Exp Immunol; 2010 Sep; 161(3):518-26. PubMed ID: 20550549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of home-based subcutaneous immunoglobulin replacement therapy in paediatric patients with primary immunodeficiencies.
    Borte M; Bernatowska E; Ochs HD; Roifman CM;
    Clin Exp Immunol; 2011 Jun; 164(3):357-64. PubMed ID: 21413943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcutaneous Immunoglobulin Replacement Therapy with Hizentra® is Safe and Effective in Children Less Than 5 Years of Age.
    Patel NC; Gallagher JL; Ochs HD; Atkinson TP; Wahlstrom J; Dorsey M; Bonilla FA; Heimall J; Kobrynski L; Morris D; Haddad E
    J Clin Immunol; 2015 Aug; 35(6):558-65. PubMed ID: 26336818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of Hizentra(®) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy.
    Jolles S; Bernatowska E; de Gracia J; Borte M; Cristea V; Peter HH; Belohradsky BH; Wahn V; Neufang-Hüber J; Zenker O; Grimbacher B
    Clin Immunol; 2011 Oct; 141(1):90-102. PubMed ID: 21705277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency.
    Church JA; Leibl H; Stein MR; Melamed IR; Rubinstein A; Schneider LC; Wasserman RL; Pavlova BG; Birthistle K; Mancini M; Fritsch S; Patrone L; Moore-Perry K; Ehrlich HJ;
    J Clin Immunol; 2006 Jul; 26(4):388-95. PubMed ID: 16705486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subcutaneous immunoglobulin: rapid push vs. infusion pump in pediatrics.
    Shapiro RS
    Pediatr Allergy Immunol; 2013 Feb; 24(1):49-53. PubMed ID: 23331529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous immunoglobulins: product characteristics and their role in primary immunodeficiency disease.
    Melamed I; Testori A; Spirer Z
    Int Rev Immunol; 2012 Dec; 31(6):451-61. PubMed ID: 23215767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency diseases.
    Kanegane H; Imai K; Yamada M; Takada H; Ariga T; Bexon M; Rojavin M; Hu W; Kobayashi M; Lawo JP; Nonoyama S; Hara T; Miyawaki T
    J Clin Immunol; 2014 Feb; 34(2):204-11. PubMed ID: 24504846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcutaneous immunoglobulin therapy given by subcutaneous rapid push vs infusion pump: a retrospective analysis.
    Shapiro RS
    Ann Allergy Asthma Immunol; 2013 Jul; 111(1):51-5. PubMed ID: 23806460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, Safety, and Tolerability of Subcutaneous Immune Globulin Injection (Human), 10 % Caprylate/Chromatography Purified (GAMUNEX®-C) in Pediatric Patients with Primary Immunodeficiency Disease.
    Heimall J; Chen J; Church JA; Griffin R; Melamed I; Kleiner GI
    J Clin Immunol; 2016 Aug; 36(6):600-9. PubMed ID: 27342758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Efficacy and Safety of Hizentra® in Patients with Primary Immunodeficiency in Japan, Europe, and the United States: a Review of 7 Phase 3 Trials.
    Jolles S; Rojavin MA; Lawo JP; Nelson R; Wasserman RL; Borte M; Tortorici MA; Imai K; Kanegane H
    J Clin Immunol; 2018 Nov; 38(8):864-875. PubMed ID: 30415311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An open, prospective trial investigating the pharmacokinetics and safety, and the tolerability of escalating infusion rates of a 10% human normal immunoglobulin for intravenous infusion (IVIg), BT090, in patients with primary immunodeficiency disease.
    Kriván G; Königs Ch; Bernatowska E; Salama A; Wartenberg-Demand A; Sonnenburg C; Linde R
    Vox Sang; 2015 Oct; 109(3):248-56. PubMed ID: 25953213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.